Levormeloxifene is a selective estrogen receptor modulator that was developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss. The development was stopped because of a high incidence of gynaecologic adverse events during clinical trials.
- Ravn P, Nielsen TF, Christiansen C. (2006). "What can be learned from the levormeloxifene experience?". Acta Obstet Gynecol Scand. 85 (2): 135–42. PMID 16532904.